|
|
Engineering Clinical Trials on a Chip for Dystrophin-Deficient Muscular Dystrophy |
| 4UH3TR003271-03 |
|
NCATS |
2022 |
|
|
Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation |
| 5R21TR004006-02 |
|
NCATS |
2022 |
|
|
Integrated Microphysiological System of Cerebral Organoid and Blood Vessel for Disease Modeling and Neuropsychiatric Drug screening |
| 5UH3TR002151-05 |
|
NCATS |
2022 |
|
|
Association of Tau and Neuronal Hypometabolism with Positron Emission Tomography in Alzheimers Disease |
| 1F30AG074524-01A1 |
|
NIA |
2022 |
|
|
Effects of metabolic phenotype on functional connectivity in aging and Alzheimer’s Disease |
| 1F30AG076278-01 |
|
NIA |
2022 |
|
|
Fluency from Flesh to Filament: Collation, Representation, and Analysis of Multi-Scale Neuroimaging data to Characterize and Diagnose Alzheimers Disease |
| 1F30AG077736-01 |
|
NIA |
2022 |
|
|
Multimodal, multiclass prediction of disease status in Alzheimer’s |
| 1F30AG079610-01 |
|
NIA |
2022 |
|
|
AMPK localization, expression, and activity in Alzheimers Disease |
| 1F30AG079633-01 |
|
NIA |
2022 |
|
|
Explaining racial and ethnic Alzheimer’s disease disparities with joint estimation of life course social inequities and measurement bias in verbal memory assessment |
| 1F31AG076284-01 |
|
NIA |
2022 |
|
|
Single-cell epigenomic roadmap of Alzheimers disease |
| 1F31AG076308-01 |
|
NIA |
2022 |